Literature DB >> 19336917

Membrane transport mechanisms of mizoribine in the rat intestine and human epithelial LS180 cells.

Kazuya Ishida1, Mari Takaai, Ayano Yotsutani, Masato Taguchi, Yukiya Hashimoto.   

Abstract

The aim of the present study was to characterize membrane transport mechanisms of mizoribine in the intestinal epithelial cells. We evaluated the contribution of Na(+)-dependent and -independent membrane transporters to mizoribine absorption in the rat intestine using an in situ closed loop method. In addition, we evaluated the effects of structurally related compounds, extracellular Na(+) concentrations, and an inhibitor of Na(+)-independent equilibrative nucleoside transporter, nitrobenzylmercaptopurine ribonucleoside (NBMPR), on the uptake of mizoribine in human intestinal epithelial LS180 cells. In the presence and also absence of Na(+) in rat intestinal loops, more than 60% of the administered dose (50 microg at the concentration of 100 microg/ml=386 microM) of mizoribine was absorbed in 40 min. In the LS180 cells, ribavirin and inosine reduced the uptake of 400 microM mizoribine with the increasing concentrations (from 5 to 50 mM) of the inhibitors. The cellular uptake of mizoribine in the absence of extracellular Na(+) decreased to 72.7% of the uptake in the presence of extracellular Na(+), whereas 100 microM NBMPR decreased the uptake of mizoribine markedly to 34.7% of that without NBMPR. These findings suggest that Na(+)-independent nucleoside transporters are largely responsible for absorption of mizoribine in the intestine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336917     DOI: 10.1248/bpb.32.741

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

1.  Population pharmacokinetics of mizoribine in adult recipients of renal transplantation.

Authors:  Kazuya Ishida; Masahiko Okamoto; Michio Ishibashi; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2011-07-14       Impact factor: 2.801

2.  The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease.

Authors:  Takuhito Nagai; Osamu Uemura; Hisashi Kaneda; Katsumi Ushijima; Kazuhide Ohta; Yoshimitsu Gotoh; Kenichi Satomura; Masaki Shimizu; Mikiya Fujieda; Masashi Morooka; Takuji Yamada; Masayoshi Yamada; Naohiro Wada; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2016-11-21       Impact factor: 2.801

3.  Population pharmacokinetics of mizoribine in pediatric patients with kidney disease.

Authors:  Hisashi Kaneda; Masaki Shimizu; Kazuhide Ohta; Katsumi Ushijima; Yoshimitsu Gotoh; Kenichi Satomura; Takuhito Nagai; Mikiya Fujieda; Masashi Morooka; Takuji Yamada; Masayoshi Yamada; Naohiro Wada; Mari Takaai; Yukiya Hashimoto; Osamu Uemura
Journal:  Clin Exp Nephrol       Date:  2015-12-09       Impact factor: 2.801

4.  Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients.

Authors:  Rui Dai; Jingjie Li; Jingjing Wu; Qian Fu; Jiajia Yan; Guoping Zhong; Changxi Wang; Xiao Chen; Pan Chen
Journal:  Eur J Clin Pharmacol       Date:  2020-08-15       Impact factor: 2.953

5.  Multiple Computational Approaches for Predicting Drug Interactions with Human Equilibrative Nucleoside Transporter 1.

Authors:  Siennah R Miller; Thomas R Lane; Kimberley M Zorn; Sean Ekins; Stephen H Wright; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2021-05-12       Impact factor: 3.579

6.  Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice.

Authors:  Aaron M Moss; Christopher J Endres; Ana Ruiz-Garcia; Doo-Sup Choi; Jashvant D Unadkat
Journal:  Mol Pharm       Date:  2012-08-03       Impact factor: 5.364

7.  The immunosuppressive agent mizoribine monophosphate is an inhibitor of the human RNA capping enzyme.

Authors:  Frédéric Picard-Jean; Isabelle Bougie; Satoshi Shuto; Martin Bisaillon
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.